Grünenthal acquires US-company Valinor Pharma and turns into worldwide proprietor of Movantik®
- Grünenthal acquires the pharmaceutical company Valinor Pharma, extra strengthening Grünenthal’s footprint in the usa.
- With the acquisition, Grünenthal turns into the worldwide proprietor of Movantik® / Moventig® (naloxegol).
- Since 2017, Grünenthal has invested more than €2 billion in a hit M&A transactions, very much strengthening its profitability.
Aachen, Germany, 22 July 2024 – Grünenthal this day launched the acquisition of US-essentially based totally mostly Valinor Pharma, LLC (“Valinor”) and its product Movantik®
(naloxegol), with a complete deal worth of approx. $250 million inclusive of all royalty responsibilities. Grünenthal will finance the transaction using accessible liquidity.
Movantik® is indicated for the oral remedy of opioid-precipitated constipation (OIC) in grownup patients with chronic non-cancer wretchedness. The transaction extra expands Grünenthal’s portfolio of established medicines and adds to the company’s rising U.S. industry. Wicked sales from Movantik® in the usa reached over $200 million in 2023.
“As a wretchedness specialist, Movantik is a excellent fit for Grünenthal with our existing customer scandalous and complementary product portfolio”, says Gabriel Baertschi, CEO, Grünenthal. “The acquisition of Valinor Pharma strengthens our footprint in the usa, the greatest boost market for Grünenthal.”
Marv Kelly, President of Grünenthal US, commented: “We’re mad to welcome Valinor and invent larger our portfolio offering to wretchedness specialists with Movantik.”
Grünenthal obtained the product in Europe (branded Moventig® exterior of the U.S.) in 2023 as phase of a joint endeavor with Kyowa-Kirin. The acquisition of Valinor makes Grünenthal the worldwide proprietor of the emblem (ex-Canada).
With Movantik®, Grünenthal continues to invent its approach of acquiring established medicines to invent larger its portfolio and invent larger the company’s profitability. Since 2017, Grünenthal has obtained plenty of established medicines, including NebidoTM, the European rights to CrestorTM and NexiumTM, moreover to the worldwide rights to VimovoTM (excluding the U.S. and Japan), QutenzaTM and ZomigTM (excluding Japan). In 2023, Grünenthal established Grünenthal Meds, a joint endeavor with Kyowa Kirin Global, which manages a portfolio of 13 producers essentially centered on wretchedness management. Grünenthal has invested more than €2 billion in a hit M&A transactions.
About Grünenthal
Grünenthal is a world leader in wretchedness management and linked ailments. As a science-essentially based totally mostly, fully constructed-in pharmaceutical company, now we maintain a protracted track sage of bringing modern therapies and notify-of-the-artwork technologies to patients worldwide. Our cause is to trade lives for the upper, and innovation is our ardour. We’re focusing all our activities and efforts on practising our imaginative and prescient of a world freed from wretchedness.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries all the plan through Europe, Latin The United States, and the U.S. Our products are accessible in in approx. 100 countries. In 2023, Grünenthal employed around 4,400 americans and performed revenues of €1.8 billion.
Extra files: www.grunenthal.com and Grünenthal File 2023/24
Follow us on:
LinkedIn: Grunenthal Neighborhood
Instagram: grunenthal
For extra files, please contact:
Florian Dieckmann, Head Global Company Affairs
Press launch dispensed by Pressat on behalf of files aktuell, on Monday 22 July, 2024. For more files subscribe and follow https://pressat.co.uk/